Reuters reported that AstraZeneca made a nonbinding proposal valued at up to approximately $10 billion to acquire Rhythm Pharmaceuticals. The reported consideration could reach $134 per share, including contingent milestone payments, while Rhythm shares rose approximately 28% to $110.68 following the reports. Rhythm markets Imcivree (setmelanotide), whose FDA-approved indications expanded in March 2026 to include acquired hypothalamic obesity. AstraZeneca declined to comment, and no definitive transaction has been announced.
Reuters
Source: Reuters, November 4
Why it matters strategically
This would potentially expand AstraZeneca's rare-disease portfolio through Alexion while providing exposure to a differentiated obesity-treatment segment.
Unlike the broader GLP-1 obesity market, Rhythm's opportunity is concentrated in patients with specific underlying causes of obesity.
The commercial question is whether regulatory expansion and additional eligible patients justify the proposed acquisition valuation.
